EDP Sciences logo
Authentification abonné
Rechercher
Menu
Accueil Tous les numéros Volume 34 (October 2018) Focus issue F1 Med Sci (Paris), 34 (2018) 8-14 Références
Accès gratuit
Numéro
Med Sci (Paris)
Volume 34, October 2018
Cancer biomarkers
Page(s) 8 - 14
DOI https://doi.org/10.1051/medsci/201834f102
Publié en ligne 7 novembre 2018
  1. MacKie RM, Hauschild A, Eggermont AM. Epidemiology of invasive cutaneous melanoma. Ann Oncol 2009; 20 Suppl 6 : vi1–7. [CrossRef] [PubMed] [Google Scholar]
  2. Rastrelli M, Tropea S, Rossi CR, Alaibac M. Melanoma: epidemiology, risk factors, pathogenesis, diagnosis and classification. In Vivo 2014 ; 28 : 1005–1011. [PubMed] [Google Scholar]
  3. Gloster HM, Jr., Neal K. Skin cancer in skin of color. J Am Acad Dermatol 2006; 55 : 741–60; quiz 61–4. [CrossRef] [PubMed] [Google Scholar]
  4. Narayanan DL, Saladi RN, Fox JL. Ultraviolet radiation and skin cancer. Int J Dermatol 2010 ; 49 : 978–986. [CrossRef] [PubMed] [Google Scholar]
  5. Sosman JA, Kim KB, Schuchter L, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012 ; 366 : 707–714. [CrossRef] [PubMed] [Google Scholar]
  6. Fedorenko IV, Paraiso KH, Smalley KS. Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma. Biochem Pharmacol 2011 ; 82 : 201–209. [CrossRef] [PubMed] [Google Scholar]
  7. Mollereau C, Parmentier M, Mailleux P, et al. ORL1, a novel member of the opioid receptor family. Cloning, functional expression and localization. FEBS Lett 1994 ; 341 : 33–38. [CrossRef] [PubMed] [Google Scholar]
  8. Shinkai H, Ito T, Iida T, et al. 4-Aminoquinolines: novel nociceptin antagonists with analgesic activity. J Med Chem 2000 ; 43 : 4667–4677. [CrossRef] [PubMed] [Google Scholar]
  9. Yamada H, Nakamoto H, Suzuki Y, et al. Pharmacological profiles of a novel opioid receptor-like1 (ORL(1)) receptor antagonist, JTC-801. Br J Pharmacol 2002 ; 135 : 323–332. [CrossRef] [PubMed] [Google Scholar]
  10. Tamai H, Sawamura S, Takeda K, et al. Anti-allodynic and anti-hyperalgesic effects of nociceptin receptor antagonist, JTC-801, in rats after spinal nerve injury and inflammation. Eur J Pharmacol 2005 ; 510 : 223–228. [CrossRef] [PubMed] [Google Scholar]
  11. Zhang Y, Simpson-Durand CD, Standifer KM. Nociceptin/orphanin FQ peptide receptor antagonist JTC-801 reverses pain and anxiety symptoms in a rat model of post-traumatic stress disorder. Br J Pharmacol 2015 ; 172 : 571–582. [CrossRef] [PubMed] [Google Scholar]
  12. Boehncke S, Hardt K, Schadendorf D, et al. Endogenous mu-opioid peptides modulate immune response towards malignant melanoma. Exp Dermatol 2011 ; 20 : 24–28. [CrossRef] [PubMed] [Google Scholar]
  13. Yamamizu K, Furuta S, Hamada Y, et al. small ka, Cyrillic Opioids inhibit tumor angiogenesis by suppressing VEGF signaling. Sci Rep 2013 ; 3 : 3213. [CrossRef] [PubMed] [Google Scholar]
  14. Yuan TL, Cantley LC. PI3K pathway alterations in cancer: variations on a theme. Oncogene 2008 ; 27 : 5497–5510. [CrossRef] [PubMed] [Google Scholar]
  15. Karbowniczek M, Spittle CS, Morrison T, et al. mTOR is activated in the majority of malignant melanomas. J Invest Dermatol 2008 ; 128 : 980–987. [CrossRef] [PubMed] [Google Scholar]
  16. Magnuson B, Ekim B, Fingar DC. Regulation and function of ribosomal protein S6 kinase (S6K) within mTOR signalling networks. Biochem J 2012 ; 441 : 1–21. [CrossRef] [PubMed] [Google Scholar]
  17. Strickland LR, Pal HC, Elmets CA, Afaq F. Targeting drivers of melanoma with synthetic small molecules and phytochemicals. Cancer Lett 2015 ; 359 : 20–35. [CrossRef] [Google Scholar]
  18. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002 ; 417 : 949–954. [CrossRef] [PubMed] [Google Scholar]
  19. Lito P, Pratilas CA, Joseph EW, et al. Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas. Cancer Cell 2012 ; 22 : 668–682. [CrossRef] [PubMed] [Google Scholar]
  20. Butour JL, Moisand C, Mazarguil H, et al. Recognition and activation of the opioid receptor-like ORL 1 receptor by nociceptin, nociceptin analogs and opioids. Eur J Pharmacol 1997 ; 321 : 97–103. [CrossRef] [PubMed] [Google Scholar]
  21. Alnemri ES, Livingston DJ, Nicholson DW, et al. Human ICE/CED-3 protease nomenclature. Cell 1996 ; 87 : 171. [CrossRef] [PubMed] [Google Scholar]
  22. Yang J, Liu X, Bhalla K, et al. Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. Science 1997 ; 275 : 1129–1132. [CrossRef] [Google Scholar]
  23. Fridman JS, Benedict MA, Maybaum J. bcl-X(S)-induced cell death in 3T3 cells does not require or induce caspase activation. Cancer Res 1999 ; 59 : 5999–6004. [Google Scholar]
  24. Gustin JP, Karakas B, Weiss MB, et al. Knockin of mutant PIK3CA activates multiple oncogenic pathways. Proc Natl Acad Sci U S A 2009 ; 106 : 2835–2840. [CrossRef] [PubMed] [Google Scholar]
  25. Kwong LN, Davies MA. Navigating the therapeutic complexity of PI3K pathway inhibition in melanoma. Clin Cancer Res 2013 ; 19 : 5310–5319. [CrossRef] [PubMed] [Google Scholar]
  26. Atefi M, von Euw E, Attar N, et al. Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway. PLoS One 2011 ; 6 : e28973. [CrossRef] [PubMed] [Google Scholar]
  27. Gopal YN, Deng W, Woodman SE, et al. Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells. Cancer Res 2010 ; 70 : 8736–8747. [CrossRef] [Google Scholar]
  28. Grove JR, Banerjee P, Balasubramanyam A, et al. Cloning and expression of two human p70 S6 kinase polypeptides differing only at their amino termini. Mol Cell Biol 1991 ; 11 : 5541–5550. [CrossRef] [PubMed] [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.